ClinicalTrials.gg
RecruitingNCT07645924Updated Nov 2, 2026

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

A Phase 3 interventional study of Elismetrep and Placebo in Migraine, sponsored by TriGemX Bio, Inc.. Recruiting at 113 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by TriGemX Bio, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 2, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,800
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 697 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Planned enrollment
13th of 610
1,800 · median 78
Started
2026
with 35 others
Phase 3
136 of 697
20 open now
Primary completion
2027-02
later than 25 of 114 live
Registered
683rd of 697
by date

Among the 697 studies in Migraine Disorders with a site in United States, this one is the 13th largest by planned enrollment of the 610 interventional ones that give a count, is one of 36 that started in 2026, is one of 136 in phase 3, reaches primary completion later than 25 of the 114 other live ones, and was the 683rd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 697 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Be a male or female, age 18 to 75 years, inclusive, at the time of signing . 2. Has greater than a one-year history of migraine with or without aura as defined by International Headache Society criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated. 3. Has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the 2 months prior to screening (Visit 1). 4. Meet the following requirements:

a. Is a male OR b. Is a female who is of non- defined by at least one of the following criteria: i. as defined by one of the following:

  1. A minimum of 12 months of spontaneous amenorrhea or
  2. A minimum of 6 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone level > 40 mIU/mL or
  3. At least 6 weeks post bilateral oophorectomy (with or without hysterectomy). OR ii. Post hysterectomy or bilateral salpingectomy, based on the participant's recall of their medical history OR c. Is a female of and: i. Agrees to remain abstinent from heterosexual activity OR ii. Agrees to use (or have their partner use) a method that is acceptable from the first dose of study drug until the End of Study visit.

Acceptable methods of birth control are:

  1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal).
  2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral; injectable; or implantable).
  3. Intrauterine device (IUD);
  4. Intrauterine hormone-releasing system (IUS);
  5. Bilateral tubal occlusion;
  6. Vasectomized partner;
  7. Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action;
  8. Male or female condom with or without spermicide;
  9. Cap, diaphragm or sponge with spermicide; a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods).

5. Voluntarily agrees to participate in the study by giving written informed consent. 6. Is able to read, understand and complete the study questionnaires and eDiary. 7. Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions. 8. Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the trial if any of the following criteria apply:

  1. Is a female who is pregnant, breast-feeding, or intends to become pregnant during the planned course of the trial.

    Migraine history-related

  2. Has difficulty distinguishing his/her migraine attacks from tension-type headaches.
  3. Has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than 2 hours.
  4. Has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the 3 months prior to screening (Visit 1).
  5. Has brainstem (also known as basilar-type) or hemiplegic migraine headache, or retinal migraine.
  6. Was >50 years old at age of first migraine onset.
  7. Is taking migraine prophylactic medication where the prescribed dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.

    Medical history related

  8. Has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia, or significant neurological disorders other than migraine [Patients who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study].
  9. Is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Patients must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.
  10. Has a recent history (within the past 3 years of the screening visit) or current diagnosis or evidence of endocrine, hematological, immunological (including Sjogren's syndrome), renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases or hepatic impairment that, per the investigator's judgement, may jeopardize the subject's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
  11. Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.
  12. Has a history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Patients with myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke or during the 6 months prior to screening.
  13. Has a history of disease.
  14. Has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption or may otherwise alter the absorption of orally administered drugs (e.g. upper gastrointestinal dysmotility).

    Laboratory, vital sign, and related

  15. Has a positive test result at screening for surface antigen, virus antibody.
  16. Has a screening estimated estimated with the Modification of Diet in Renal Disease (MDRD) equation of \<30 mL/min/1.73 m2.
  17. Has a screening result for or aspartate aminotransferase of >2.0 X (ULN) or total >1.5 X ULN at the Screening visit. Note: An isolated bilirubin >1.5 X ULN is acceptable if bilirubin is fractionated and direct bilirubin is within the laboratory normal range.
  18. Has a mean value for triplicate interval to Fridericia's formula (QTcF) >450 ms for males and >470 ms for females at screening.
  19. Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure >95 mmHg measured after at least 5 minutes at rest at the Screening Visit. Note: If a participant's blood pressure is exclusionary on the first triplicate assessment at the Screening Visit, they may have one repeat triplicate blood pressure assessment at that visit after another rest of at least 10 minutes.

    Medication use and substance abuse related

  20. Has known history of or suspected abuse of alcohol or recreational drugs at Screening.
  21. Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol [THC] or cannabidiol [CBD] within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.
  22. Has a positive drug screen at screening. Note:

    1. If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g., for insomnia) and confirmatory documentation is obtained from the prescribing physician.
    2. If amphetamines are detected on the drug screen, this is not exclusionary if the participant is taking a stimulant medication for a therapeutic purpose (e.g., Adderall for attention deficit hyperactivity disorder), confirmatory documentation is obtained from the prescribing physician, and the stimulant medication in question is known to be detected as amphetamine on the drug screen being used.
  23. Is currently in violation of study requirements for prohibited and permissible concomitant medications or treatments (not already specified in other criteria) or is anticipated to violate these requirements during study participation (detailed in the protocol). Note: Any use of the following within 8 weeks of the screening visit, or anticipated use at any point during study participation are exclusionary:

    1. Devices for the acute and/or preventative treatment of headache (migraine and/or other type of headache)
    2. Nerve blocks and/or trigger point injections for the acute and/or preventative treatment of headache (migraine and/or other type of headache).
  24. Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.
  25. Has a history of use of ergotamine medications ≥10 days per month on a regular basis for ≥3 months prior to screening.
  26. Has a history of non-narcotic analgesic intake ≥15 days per month for ≥3 months prior to screening.

    Other

  27. Has known or suspected to trial product(s) or related products.
  28. Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
  29. Has any surgery scheduled for the duration of the trial.
  30. Has a screening \<11.0 g/dL (males) or \<10.0 g/dL (females) or has a known hemoglobinopathy (e.g., sickle cell anemia, hemolytic anemia).
  31. Has previous participation in this trial. Participation is defined as signed .
  32. Has participated in any clinical trial of an approved or non-approved biological medicinal product (e.g., antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening or ever signed an informed consent for Study K-304 P004. Note: Patients may not be screened at more than one trial site for this study.
  33. Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
  34. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,800 participants (estimated)

Study arms

  • Experimental
    Elismetrep 10 mg

    Drug: Elismetrep

  • Experimental
    Elismetrep 20 mg

    Drug: Elismetrep

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered orally

    Also known as: K-304

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Pain freedom at 2 hours post-dose

    Percentage of participants that report no pain at 2 hours post-dose. Pain will be measured on a 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).

    Time frame: Two hours post-dose

  2. Freedom from most bothersome symptoms (MBS) at 2 hours post-dose

    Percentage of participants that report absence of their MBS (nausea, phonophobia, or photophobia) at 2 hours post-dose. MBS will be measured using a binary scale (0=absent, 1=present).

    Time frame: Two hours post-dose

Secondary outcomes

  1. Pain relief at 2 hours post-dose

    Percentage of participants that report a pain level of moderate of severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then report a pain level of none or mild (responses of 0 or 1 on the 4-point Likert scale) at 2 hours post-dose.

    Time frame: Two hours post-dose

  2. Sustained pain freedom from 2 to 48 hours post-dose

    Percentage of participants that do not use any rescue medication, do not experience any headache pain through the time period of interest, and do not have missing pain data at 2, 24, or 48hours post-dose.

    Time frame: From 2 to 48 hours post-dose

  3. Freedom from functional disability at 2 hours post-dose

    Percentage of participants that self-report as being able to function normally on the functional disability scale in the subset of participants that reported any level of disability at baseline. The scale has a 4-point numeric rating: normal (0); mildly impaired (1); moderately impaired (2); severely impaired, requires bedrest (3).

    Time frame: Two hours post-dose

  4. Pain relief at 60 minutes post-dose

    Percentage of participants that report a pain level of moderate of severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then report a pain level of none or mild (responses of 0 or 1 on the 4-point Likert scale) at 60 minutes post-dose

    Time frame: Sixty minutes post-dose

  5. Proportion requiring rescue medication within 24 hours post-dose

    Percentage of participants that take rescue medication within 24 hours post-dose.

    Time frame: Within 24 hours post-dose

  6. Freedom from photophobia at 2 hours post-dose

    Percentage of participants that report the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline.

    Time frame: Two hours post-dose

  7. Freedom from phonophobia at 2 hours post-dose

    Percentage of participants that report the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline.

    Time frame: Two hours post-dose

  8. Freedom from nausea at 2 hours post-dose

    Percentage of participants that report the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline.

    Time frame: Two hours post-dose

  9. Sustained pain freedom from 2 to 24 hours post-dose

    Percentage of participants that do not use any rescue medication, do not experience any headache pain through the time period of interest, and do not have missing pain data at 2 or 24 hours post-dose.

    Time frame: From 2 to 24 hours post-dose

  10. Sustained pain relief from 2 to 48 hours post-dose

    Percentage of participants that do not use any rescue medications, do not experience any moderate or severe headache pain through the time period of interest, and do not have missing pain data at 2, 24, or 48 hours post-dose.

    Time frame: From 2 to 48 hours post-dose

  11. Sustained pain relief from 2 to 24 hours post-dose

    Percentage of participants that do not use any rescue medications, do not experience any moderate or severe headache pain through the time period of interest, and do not have missing pain data at 2 or 24 hours post-dose.

    Time frame: From 2 to 24 hours post-dose

  12. Pain relapse from 2 to 48 hours post-dose

    Percentage of participants that are pain free at 2 hours post-dose and have (a) mild, moderate, or severe pain (response of 1, 2, or 3 on the 4-point Likert scale) at any time point after 2 hours post-dose, or (b) missing pain data at 24 hours or 48 hours after 2 hours post-dose, or (c) intervening rescue medication use at or before 48 hours post-dose.

    Time frame: From 2 to 48 hours post-dose

  13. Percentage of participants who experience one or more treatment-emergent adverse events (AEs)

    Time frame: Up to 8 days post-dose

  14. Percentage of participants who experience one or more treatment-emergent serious adverse events (SAEs)

    Time frame: Up to 8 days post-dose

07

Study locations

113 of 113 sites recruiting
  • Central Research Associates, LLC (CRA) dba Flourish Research
    Birmingham, Alabama 35205, United States
    Recruiting
    • · Contact(205) 327-1077
  • AMR Mobile
    Mobile, Alabama 36608, United States
    Recruiting
    • · Contact(251) 901-2127
  • TrialSphere
    Chandler, Arizona 85286, United States
    Recruiting
    • · Contact(623) 267-8314
  • Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
    Recruiting
    • · Contact(501) 480-5088
  • Axiom Research, LLC
    Colton, California 92324, United States
    Recruiting
    • · Contact(909) 824-2325
  • ProScience Research Group
    Culver City, California 90230, United States
    Recruiting
    • · Contact(424) 227-8127
  • Leading Edge Research LA, LLC
    Encino, California 91316, United States
    Recruiting
    • · Contact(818) 578-4555
  • Axiom Research, Orange County
    Irvine, California 92604, United States
    Recruiting
    • · Contact(909) 824-2325
  • Downtown L.A. Research Center, Inc.
    Los Angeles, California 90017, United States
    Recruiting
    • · Contact(213) 261-3680
  • Clinical Research Institute
    Los Angeles, California 90048, United States
    Recruiting
    • · Contact(323) 879-9999
  • M3 Wake Research - Mission Mental Health (WR-MMH)
    Mission Viejo, California 92691, United States
    Recruiting
    • · Contact(949) 752-7910
  • Excell Research
    Oceanside, California 92056, United States
    Recruiting
    • · Contact(760) 758-2222
  • Empire Clinical Research
    Pomona, California 91767, United States
    Recruiting
    • · Contact(909) 981-5321
  • The Neurology Group
    Pomona, California 91767, United States
    Recruiting
    • · Contact(909) 982-2719
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
    Recruiting
    • · Contact(855) 367-8834
  • Acclaim Clinical Research
    San Diego, California 92120, United States
    Recruiting
    • · Contact(855) 367-8834
  • CenExel Sherman Oaks CA (California Neuroscience Research)
    Sherman Oaks, California 91403, United States
    Recruiting
    • · Contact(818) 990-2671
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
    Recruiting
    • · Contact(619) 660-9068
  • Sunwise Clinical Research
    Walnut Creek, California 94596, United States
    Recruiting
    • · Contact(925) 298-5147
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
    Recruiting
    • · Contact(925) 930-7267
  • Kinetic Clinical Research
    West Covina, California 91790, United States
    Recruiting
    • · Contact(657) 230-7120
  • Focus Clinical Research
    West Hills, California 91307, United States
    Recruiting
    • · Contact(818) 253-8966
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
    Recruiting
    • · Contact(303) 771-9000
  • MCB Clinical Research Centers
    Colorado Springs, Colorado 80910, United States
    Recruiting
    • · Contact(719) 634-6576
  • Advanced Neurosciences Research
    Fort Collins, Colorado 80528, United States
    Recruiting
    • · Contact(970) 226-6111
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
    Recruiting
    • · Contact(203) 419-4404
  • DelRicht Research
    Atlanta, Georgia 30329, United States
    Recruiting
    • · Contact(770) 417-4454
  • Drug Studies America
    Marietta, Georgia 30060, United States
    Recruiting
    • · Contact(678) 581-5252
  • Sleep Care Research Institute d/b/a Clinical Research Atlanta-Stockbridge
    Stockbridge, Georgia 30281, United States
    Recruiting
    • · Contact(770) 626-0177
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
    Recruiting
    • · Contact(312) 431-6780
  • Chicago Headache Center & Research Institute
    Chicago, Illinois 60657, United States
    Recruiting
    • · Contact(773) 935-1000
  • Healthcare Research Network II, LLC
    Flossmoor, Illinois 60477, United States
    Recruiting
    • · Contact(708) 388-2245
  • Chicago Headache Center & Research Institute
    Naperville, Illinois 60563, United States
    Recruiting
    • · Contact(415) 397-0700
  • Integrated Clinical Trials Solution
    West Des Moines, Iowa 50265, United States
    Recruiting
    • · Contact(515) 223-2300
  • Collective Medical Research
    Overland Park, Kansas 66212, United States
    Recruiting
    • · Contact(913) 381-7180
  • Clinical Associates Midwest, LLC
    Overland Park, Kansas 66214, United States
    Recruiting
    • · Contact(913) 359-5699
  • Heartland Research Associates, LLC - An AMR Company
    Wichita, Kansas 67207, United States
    Recruiting
    • · Contact(316) 689-6635
  • Physicians to Children & Adolescents, PSC (Kentucky Pediatric / Adult Research)
    Bardstown, Kentucky 40004, United States
    Recruiting
    • · Contact(502) 349-1569
  • AMR Clinical - Lexington
    Lexington, Kentucky 40509, United States
    Recruiting
    • · Contact(859) 264-8999
  • CTI Clinical Research Center
    Lexington, Kentucky 45212, United States
    Recruiting
    • · Contact(513) 721-3868
  • Crescent City Headache & Neurology Center
    Chalmette, Louisiana 70043, United States
    Recruiting
    • · Contact(504) 418-6040
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
    Recruiting
    • · Contact(504) 336-2667
  • Headlands Research - PharmaSite
    Pikesville, Maryland 21208, United States
    Recruiting
    • · Contact(410) 602-1440
  • Boston Clinical Trials - Alcanza
    Boston, Massachusetts 02131, United States
    Recruiting
    • · Contact(843) 856-3784
  • MedVadis Research Corporation, LLC
    Waltham, Massachusetts 02451, United States
    Recruiting
    • · Contact(781) 373-2940
  • Michigan Headache Pain & Neurological Institute
    Ann Arbor, Michigan 48104, United States
    Recruiting
    • · Contact(734) 677-6000
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
    Recruiting
    • · Contact(612) 333-2200
  • DelRicht Research
    Gulfport, Mississippi 39503, United States
    Recruiting
    • · Contact(228) 588-8268
  • Proven Endpoints
    Ridgeland, Mississippi 39157, United States
    Recruiting
    • · Contact(601) 790-1811
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
    Recruiting
    • · Contact(636) 387-5100
  • Healthcare Research Network
    Hazelwood, Missouri 63042, United States
    Recruiting
    • · Contact(314) 972-9600
  • AMR Clinical - Kansas City
    Kansas City, Missouri 64114, United States
    Recruiting
    • · Contact(816) 643-4153
  • Clinvest Headlands LLC
    Springfield, Missouri 65807, United States
    Recruiting
    • · Contact(417) 883-7889
  • Sundance Clinical Research
    St Louis, Missouri 63141, United States
    Recruiting
    • · Contact(314) 567-3377
  • IMA Clinical Research - Las Vegas
    Las Vegas, Nevada 89102, United States
    Recruiting
    • · Contact(702) 527-7401
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States
    Recruiting
    • · Contact(702) 680-1500
  • Wake Research Las Vegas Rainbow
    Las Vegas, Nevada 89118, United States
    Recruiting
    • · Contact(702) 893-8968
  • AMR Clinical - Las Vegas
    Las Vegas, Nevada 89119, United States
    Recruiting
    • · Contact(702) 529-0153
  • Redbird Research
    Las Vegas, Nevada 89119, United States
    Recruiting
    • · Contact(702) 577-2000
  • Las Vegas Clinical Trials
    North Las Vegas, Nevada 89030, United States
    Recruiting
    • · Contact(702) 637-3223
  • Advanced Research Institute - Reno
    Reno, Nevada 89511, United States
    Recruiting
    • · Contact(775) 502-1616
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
    Recruiting
    • · Contact(505) 224-7407
  • Dent Neuro Institute, Buffalo
    Amherst, New York 14226, United States
    Recruiting
    • · Contact(716) 250-2017
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
    Recruiting
    • · Contact(646) 747-4060
  • True North Neurology
    Commack, New York 11725, United States
    Recruiting
    • · Contact(631) 364-9119
  • Central New York Clinical Research
    Manlius, New York 13104, United States
    Recruiting
    • · Contact(315) 682-3263
  • Fieve Clinical Research, Inc
    New York, New York 10017, United States
    Recruiting
    • · Contact(212) 772-3570
  • Rochester Clinical Research
    Rochester, New York 14609, United States
    Recruiting
    • · Contact(585) 288-0890
  • Upstate Clinical Research Associates
    Williamsville, New York 14221, United States
    Recruiting
    • · Contact(716) 626-6320
  • OnSite Clinical Solutions
    Charlotte, North Carolina 28277, United States
    Recruiting
    • · Contact(800) 785-3150
  • Guildford Neurologic Research Partners, LLC
    Greensboro, North Carolina 27405, United States
    Recruiting
    • · Contact(336) 516-9103
  • Headache Wellness Center
    Greensboro, North Carolina 27405, United States
    Recruiting
    • · Contact(336) 574-8000
  • Eximia Research - NC, LLC
    Raleigh, North Carolina 27607, United States
    Recruiting
    • · Contact(919) 800-5154
  • Carolina Research Center, Inc
    Shelby, North Carolina 28150, United States
    Recruiting
    • · Contact(704) 487-5228
  • Hometown Research
    Columbus, Ohio 43228, United States
    Recruiting
    • · Contact(614) 362-3980
  • Hometown Research
    Milford, Ohio 45150, United States
    Recruiting
    • · Contact(513) 831-5900
  • CincyScience
    West Chester, Ohio 45069, United States
    Recruiting
    • · Contact(513) 646-4864
  • OK Clinical Research, LLC
    Edmond, Oklahoma 73034, United States
    Recruiting
    • · Contact(405) 285-6811
  • Hightower Clinical
    Oklahoma City, Oklahoma 73102, United States
    Recruiting
    • · Contact(405) 479-8331
  • DelRicht Research
    Tulsa, Oklahoma 74133, United States
    Recruiting
    • · Contact(918) 932-2276
  • Tekton Research, Inc.
    Yukon, Oklahoma 73099, United States
    Recruiting
    • · Contact(405) 281-3433
  • Summit Research Network
    Portland, Oregon 97210, United States
    Recruiting
    • · Contact(855) 367-8834
  • Advanced Research Institute - Portland
    Portland, Oregon 97223, United States
    Recruiting
    • · Contact(503) 610-0033
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18103, United States
    Recruiting
    • · Contact(818) 578-4555
  • Clinical Research Philadelphia
    Philadelphia, Pennsylvania 19114, United States
    Recruiting
    • · Contact(215) 676-6696
  • Preferred Primary Care Physicians, Inc.
    Pittsburgh, Pennsylvania 15236, United States
    Recruiting
    • · Contact(412) 650-6155
  • Frontier Clinical Research, LLC
    Scottdale, Pennsylvania 15683, United States
    Recruiting
    • · Contact(724) 220-5281
  • Frontier Clinical Research, LLC
    Smithfield, Pennsylvania 15478, United States
    Recruiting
    • · Contact(724) 569-8036
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
    Recruiting
    • · Contact(843) 856-3784
  • WR-ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
    Recruiting
    • · Contact(423) 698-4584
  • Access Clinical Trials, Inc
    Nashville, Tennessee 37203, United States
    Recruiting
    • · Contact(615) 320-6076
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
    Recruiting
    • · Contact(615) 329-0197
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
    Recruiting
    • · Contact(512) 380-9925
  • Tekton Research
    Austin, Texas 78745, United States
    Recruiting
    • · Contact(512) 859-3834
  • APD Clinical Research
    Cypress, Texas 77372, United States
    Recruiting
    • · Contact(281) 315-4986
  • Horizon Clinical Research and Gill Neuroscience
    Cypress, Texas 77429, United States
    Recruiting
    • · Contact(949) 491-0710
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75251, United States
    Recruiting
    • · Contact(214) 361-7700
  • Victorium Clinical Research
    Houston, Texas 77024, United States
    Recruiting
    • · Contact(832) 203-7026
  • DM Clinical Research
    Houston, Texas 77081, United States
    Recruiting
    • · Contact(346) 550-9559
  • GMG Clinical Research, LLC dba Radiance Clinical Research
    Lampasas, Texas 76550, United States
    Recruiting
    • · Contact(512) 556-4130

Showing the first 100 of 113 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 7 months after the start.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 7 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 12, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Kallyope Inc.→TriGemX Bio, Inc.
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Sponsor Kallyope Inc.→TriGemX Bio, Inc.
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07645924
Lead sponsor
TriGemX Bio, Inc.
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jul 1, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Annemarie Vance
Contact
annemarie@kallyope.com
917-336-3654

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elismetrep

Start the discussion